First Manhattan
IMRX icon

First Manhattan’s Immuneering IMRX Stock Holding History

First Manhattan’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Hold
24,245
– – ﹤0.01% 732
2026
Q1 		$128K Hold
24,245
– – ﹤0.01% 736
2025
Q4 		$160K Hold
24,245
– – ﹤0.01% 708
2025
Q3 		$170K Sell
24,245
-8,080
-25% -$41.9K ﹤0.01% 692
2025
Q2 		$109K Hold
32,325
– – ﹤0.01% 685
2025
Q1 		$49.1K Hold
32,325
– – ﹤0.01% 668
2024
Q4 		$71.1K Buy
+32,325
New +$67K ﹤0.01% 671
2024
Q3 		– Sell
-74,250
Closed -$95K – 688
2024
Q2 		$95K Buy
74,250
+41,000
+123% +$67.4K ﹤0.01% 652
2024
Q1 		$96.1K Buy
+33,250
New +$186K ﹤0.01% 775

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

First Manhattan's IMRX Position: Q2 2026 in Review

First Manhattan held its Immuneering (IMRX) position steady in Q2 2026 at 24,245 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #732.

First Manhattan first reported a position in IMRX in Q1 2024 and has held it in 9 quarters since. The position peaked at $170K in Q3 2025. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • First Manhattan held 24,245 shares of Immuneering worth $121K as of Q2 2026.
  • First Manhattan left its Immuneering share count unchanged in Q2 2026.
  • Immuneering made up ﹤0.01% of First Manhattan's portfolio in Q2 2026, its #732 holding.
  • First Manhattan first reported a position in Immuneering in Q1 2024 and has held it in 9 quarters since.
  • First Manhattan's Immuneering position peaked at $170K in Q3 2025.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on First Manhattan's 13F filing for Q2 2026, filed 14 Aug 2026.